Porth Ymchwil

Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

StandardStandard

Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. / Plumpton, Catrin; Alfirevic, Ana; Pirmohamed, Munir et al.
Yn: Rheumatology, Cyfrol 56, Rhif 10, 01.10.2017, t. 1729-1739.

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

HarvardHarvard

Plumpton, C, Alfirevic, A, Pirmohamed, M & Hughes, D 2017, 'Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout', Rheumatology, cyfrol. 56, rhif 10, tt. 1729-1739. https://doi.org/10.1093/rheumatology/kex253

APA

Plumpton, C., Alfirevic, A., Pirmohamed, M., & Hughes, D. (2017). Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology, 56(10), 1729-1739. https://doi.org/10.1093/rheumatology/kex253

CBE

Plumpton C, Alfirevic A, Pirmohamed M, Hughes D. 2017. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology. 56(10):1729-1739. https://doi.org/10.1093/rheumatology/kex253

MLA

Plumpton, Catrin et al. "Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout". Rheumatology. 2017, 56(10). 1729-1739. https://doi.org/10.1093/rheumatology/kex253

VancouverVancouver

Plumpton C, Alfirevic A, Pirmohamed M, Hughes D. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology. 2017 Hyd 1;56(10):1729-1739. Epub 2017 Gor 14. doi: 10.1093/rheumatology/kex253

Author

Plumpton, Catrin ; Alfirevic, Ana ; Pirmohamed, Munir et al. / Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Yn: Rheumatology. 2017 ; Cyfrol 56, Rhif 10. tt. 1729-1739.

RIS

TY - JOUR

T1 - Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

AU - Plumpton, Catrin

AU - Alfirevic, Ana

AU - Pirmohamed, Munir

AU - Hughes, Dyfrig

PY - 2017/10/1

Y1 - 2017/10/1

N2 - (ICER) of £44,954 per QALY gained. The probability of testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38,478 per QALY gained. Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.

AB - (ICER) of £44,954 per QALY gained. The probability of testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38,478 per QALY gained. Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.

U2 - 10.1093/rheumatology/kex253

DO - 10.1093/rheumatology/kex253

M3 - Article

VL - 56

SP - 1729

EP - 1739

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 10

ER -